|
- National Comprehensive Cancer Network - Home
NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives
- Experts Unpack the Most Notable NCCN Guideline Changes Heading Into . . .
Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026
- JNCCN
Highlights of the NCCN 2025 Annual Congress: Hematologic Malignancies Emerging Treatment Options for Relapsed Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
- Conexiant - National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education
- NCCN Summit Seeks to Improve Care for Veterans and First Responders . . .
The National Comprehensive Cancer Network ® (NCCN ®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education
- Novel Pharmacotherapies and NCCN Guideline Recommendations
What is their role in current practice? What are the current NCCN guideline recommendations for treating desmoid tumors in patients? How do you utilize these in your daily practice?
- National Comprehensive Cancer Network (NCCN) | Moffitt
As an NCCN member, Moffitt plays a critical role in improving the quality, effectiveness and efficiency of cancer care so that patients can live better lives The center is also at the core of establishing national guidelines of cancer care
- NCCN Updates Guidelines for Non–Small Cell Lung Cancer
In an article on the American Medical Journal website, the authors summarized the updated National Comprehensive Cancer Network (NCCN) Guidelines for non–small cell lung cancer (NSCLC), detailing expanded systemic therapy options to improve clinical outcomes for patients with resectable and unresectable disease The revised guidelines incorporate significant changes based on phase III data
|
|
|